Tetanus is an infection characterized by a state of generalized hypertonia that manifests in the form of painful muscle spasms of the jaw and neck caused by the toxin-producing anaerobe *Clostridium tetani* found mainly in the soil. We will cover pathogenesis, risk factors, clinical presentation, management and complications associated with tetanus.
|
Generalized tetanus
|
|
Neonatal tetanus
|
|
Localized tetanus
|
|
Cerebral tetanus
|
|
Generalized Tetanus
|
typically have symptoms of autonomic over-activity. Tonic and periodic spastic muscular contractions are responsible for most of the classic clinical findings of tetanus such as: ●Stiff neck ●Opisthotonus ●Risus sardonicus (sardonic smile) ●A board-like rigid abdomen ●Periods of apnea and/or upper airway obstruction due to vise-like contraction of the thoracic muscles and/or glottal or pharyngeal muscle contraction, respectively ●Dysphagia
|
|
Duration of illness
|
Tetanus toxin-induced effects are long lasting because recovery is believed to require the growth of new axonal nerve terminals. The usual duration of clinical tetanus is four to six weeks.
|
|
1. Unvaccinated mother
|
|
2. Home delivery
|
|
3. Septic cutting of the umbilical cord
|
|
4. Neonatal tetanus in a previous child
|
|
5. Infectious substances applied to the umbilical stump, such as animal dung, mud
|
|
Treatment modality
|
Advantages and Disadvantage
|
Summary of findings and level of confidence
|
Recommendation
|
|
Halting toxin production
|
|||
|
Wound management
|
Eliminate conditions ideal for spore germination
|
All patients with tetanus should undergo wound debridement to eradicate spores and necrotic tissue
|
|
|
Antimicrobial therapy
|
Metronidazole use has a theoretical advantage over penicillin use as the latter can potentially facilitate tetanospasmin activity
|
The first study to compare penicillin and metronidazole found a greater reduction in mortality in the metronidazole group. However, in three subsequent studies, there was no difference in mortality in patients treated with penicillin and those treated with metronidazole. In one of the former studies, patients receiving metronidazole required fewer muscle relaxants and sedatives. Level of confidence B
|
Metronidazole (500 mg intravenously [IV] every six to eight hours) is the preferred treatment for tetanus, but penicillin G (2 to 4 million units IV every four to six hours) is a safe and effective alternative. Suggested treatment duration of 7 to 10 days
|
|
Neutralization of unbound toxin
|
|||
|
Administration of immunoglobulins
|
Administration of immunoglobulins is beneficial. The best route of administration (intramuscular alone versus intrathecal plus intramuscular) is debatable
|
Evidence from two meta-analyses are conflicting
|
Human tetanus immune globulin (HTIG) is the preparation of choice. recommend a single dose of 500 units intramuscularly. The previously recommended dose range was 3000 to 6000 units. Given as soon as the diagnosis of tetanus is considered, with part of the dose infiltrated around the wound
|
|
Control of muscle spasms
|
|||
|
Benzodiazepines and other sedatives
|
Advantages: combined sedative, anticonvulsant and muscle relaxant effects Disadvantages: prolonged duration of action with long-acting drugs.
|
Used as standard therapy
|
Usual starting dose of diazepam for an adult is 10 to 30 mg IV and repeated as needed every 1 to 4 hours.
|
|
Neuromuscular blocking agents
|
Used when sedation alone is inadequate. Pancuronium, a long-acting agent, has been traditionally used, but it may worsen autonomic instability because it is an inhibitor of catecholamine reuptake
|
Evidence is limited to a few case series (level of evidence C)
|
Vecuronium or other cardiovascular inert neuromuscular blockers are preferred. Intrathecal baclofen given as an initial bolus in a dose ranging from 40 to 200 mcg followed by a continuous infusion of 20 mcg/hour was found to control spasms and rigidity
|
|
Autonomic dysfunction
|
|||
|
Magnesium sulphate
|
Advantages: readily available in resource-limited settings, has anticonvulsant, muscle relaxant properties, Disadvantages: needs close monitoring, Risk of hypocalcaemia, Less effective in severe disease
|
Meta-analysis shows no mortality benefit (level of evidence A)
|
Magnesium sulfate (loading dose 40 mg/kg over 30 minutes, followed by continuous infusion of either 2 g per hour for patients over 45 kg or 1.5 g per hour for patients ≤45 kg). During magnesium infusion, the patellar reflex needs to be monitored
|
|
Beta blockade
|
Labetalol has frequently been administered because of its dual alpha- and betablocking properties. Beta blockade alone (propranolol)should be avoided because of reports of sudden death
|
Evidence limited to case reports and few case series (level of evidence C)
|
Use may be reasonable on a case by case basis Labetalol (0.25 to 1 mg/min) Morphine sulfate (0.5 to 1 mg/kg per hour by continuous intravenous infusion)
|
|
Prophylactic treatment with sucralfate or protein pump inhibitors may be used to prevent gastroesophageal hemorrhage from stress ulceration
|
|
Prophylaxis of thromboembolism with heparin, low molecular weight heparin, or other anticoagulants should be administered early
|
|
Physical therapy should be started as soon as spasms have ceased, since tetanus patients often are left with disability from prolonged muscle wasting and contractures
|
|
All patients require full tetanus toxoid immunization at recovery; having the infection does not give future immunity
|
|
1. Drug-induced dystonias such as those due to phenothiazines
|
|
2. Trismus due to dental infection
|
|
3. Strychnine poisoning due to ingestion of rat poison
|
|
4. Malignant neuroleptic syndrome
|
|
5. Stiff-person syndrome
|
|
Vocal cord paralysis leading to respiratory distress
|
|
Hysteria
|
|
Neoplasms
|
|
Malignant hyperthermia
|
|
Autonomic dysfunction- leading to hypertension
|
|
Asphyxia
|
|
Long bone fractures
|
|
Paralytic ileus
|
|
Joint dislocation
|
|
Aspiration pneumonia
|
|
Pressure sores
|
|
Stress ulcers
|
|
Coma
|
|
Nerve palsy
|
|
Urine retention
|
|
Seizures
|
|
Bae C, Bourget D. Tetanus. [Updated 2020 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459217/
|
|
Centers for Disease Control and Prevention. Tetanus. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt16-tetanus.html (Accessed on February 24, 2020).
|
|
Kyu HH, Mumford JE, Stanaway JD, et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health 2017; 17:179.
|
|
Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care 2014; 18:217.
|
|
Yen LM, Dao LM, Day NPJ. Management of tetanus: a comparison of penicillin and metronidazole. Symposium of antimicrobial resistance in southern Viet Nam, 1997.
|
|
Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet 2006; 368:1436.
|
|
Buchanan N, Smit L, Cane RD, De Andrade M. Sympathetic overactivity in tetanus: fatality associated with propranolol. Br Med J 1978; 2:254.
|
No comments yet.
Cheatography n. The art of mapping complex subjects into clear, instantly navigable reference guides.